Risk Factors Associated with Increased Morbidity in Living Liver Donation

Helry L Candido1, Eduardo A da Fonseca1, Flávia H Feier1

  • 1Hepatology and Liver Transplantation, Hospital Sírio-Libanês, Rua Barata Ribeiro 414, cj 65, 01308-000 Bela Vista, SP, Brazil; Hepatology and Liver Transplantation, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.

Insights

Living donor liver donation (LDLD) carries risks. Right lobe resection, smoking, and blood transfusions significantly increase the likelihood of postoperative complications (POCs) in living liver donors.

Area of Science:

  • Transplantation Surgery
  • Hepatobiliary Surgery
  • Surgical Risk Assessment

Background:

  • Living donor liver donation (LDLD) is a vital alternative to deceased donor liver transplantation.
  • Assessing and mitigating risks for living donors is crucial for the success of LDLD programs.

Purpose of the Study:

  • To identify risk factors for postoperative complications (POCs) in living liver donors.
  • To develop a predictive score for POCs following LDLD.

Main Methods:

  • Retrospective cohort study of 688 living liver donors (June 1995 - February 2014).
  • Analysis included donor demographics, surgical factors (resection type), and outcomes.
  • Primary outcome: POCs graded ≥III (Clavien-Dindo classification).

Main Results:

  • Overall POC rate was 6.2% (43/688 donors).
  • Right lobe resection (RL) had a significantly higher POC rate (16.1%) compared to left lateral segment (4.5%) and left lobe (5.5%) resections.
  • Independent risk factors for POCs included RL resection, smoking status, and intraoperative blood transfusion.

Conclusions:

  • Right lobe resection, smoking, and intraoperative blood transfusion are significant risk factors for POCs in living liver donors.
  • These factors should be considered when evaluating donor safety and developing predictive models for LDLD.

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
682
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
763
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K